Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE‐LY trial

By  

JOURNAL OF INTERNAL MEDICINE, Vol. 283, Iss. 3, 2018-03 ,pp. : 282-292

John Wiley & Sons Inc

Access to resources Recommend Favorite

Re: Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation

By  

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 27, Iss. 2, 2018-02 ,pp. : 243-243

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of Hyperthyroidism on the Hypercoagulable State and Thromboembolic Events in Patients with Atrial Fibrillation

By  

Cardiology, Vol. 127, Iss. 3, 2014-01 ,pp. : 176-182

Karger

Access to resources Recommend Favorite

Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 11, 2015-11 ,pp. : 2119-2126

John Wiley & Sons Inc

Access to resources Recommend Favorite

Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials

By Deitelzweig Steve   Amin Alpesh   Jing Yonghua   Makenbaeva Dinara   Wiederkehr Daniel   Lin Jay   Graham John  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1163-1168

Informa Healthcare

Access to resources Recommend Favorite